

Part VI: Summary of the Risk Management Plan

Summary of risk management plan for Sitagliptin Zentiva/Jazeta (Sitagliptin)

This is a summary of the risk management plan (RMP) for Sitagliptin Zentiva/Jazeta. The RMP details important risks of Sitagliptin Zentiva/Jazeta and how more information will be obtained about Sitagliptin Zentiva/Jazeta's risks and uncertainties (missing information).

Sitagliptin Zentiva/Jazeta's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Sitagliptin Zentiva/Jazeta should be used.

Important new concerns or changes to the current ones will be included in updates of Sitagliptin Zentiva/Jazeta's RMP.

I. The medicine and what it is used for

Sitagliptin Zentiva/Jazeta is authorised for treatment in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels. It is used in addition to diet and exercise in the following ways:

- on its own, in patients who are not satisfactorily controlled on diet and exercise and in whom metformin (an antidiabetes medicine) is not suitable;
- in combination with metformin or a PPAR-gamma agonist (a type of antidiabetes medicine) such as a thiazolidinedione, in patients who are not satisfactorily controlled on metformin or the PPARgamma agonist used on its own;
- in combination with a sulphonylurea (another type of antidiabetes medicine) in patients who are not satisfactorily controlled with a sulphonylurea used on its own and in whom metformin is not suitable;
- in combination with both metformin, and a sulphonylurea or a PPAR-gamma agonist, in patients who are not satisfactorily controlled on the two medicines;
- in combination with insulin, with or without metformin, in patients who are not satisfactorily controlled on a stable dose of insulin. (see SmPC for the full indication).

It contains Sitagliptin as the active substance and it is given by oral route of administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Sitagliptin Zentiva/Jazeta, together with measures to minimise such risks and the proposed studies for learning more about Sitagliptin Zentiva/Jazeta's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Sitagliptin Zentiva/Jazeta are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Sitagliptin Zentiva/Jazeta. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	Pancreatic cancer
Missing information	Exposure during pregnancy and lactation

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Sitagliptin Zentiva/Jazeta.

II.C.2 Other studies in post-authorisation development plan There are no studies required for Sitagliptin Zentiva/Jazeta.